THC & Politics

July 19, 2026

# THC & Politics: Federal Legalization Moves Forward as States Chart Competing Courses

A coalition of hemp businesses sued Missouri this week to block a statewide ban on intoxicating hemp products set to take effect November 12, arguing the legislation contains "unconstitutionally vague" definitions that leave businesses, law enforcement, and prosecutors confused about what's actually illegal. The lawsuit, filed in U.S. District Court for the Western District, names Governor Mike Kehoe, Attorney General Catherine Hanaway, and the director of the Missouri Department of Health and Senior Services as defendants. MNG 2005, Inc.—parent company of 55 CBD Kratom stores nationwide—joined the Missouri Hemp Trade Association and Wisconsin-based Lifted Liquids Inc. in the challenge. 💰 MONEY MOVES The legislation would eliminate a product category currently sold in smoke shops with THC concentrations as high as 1,000 mg, removing a revenue stream that exists entirely outside Missouri's licensed marijuana dispensary system. Rep. Dave Hinman, the Republican sponsor of the ban, framed the lawsuit as a "Hail Mary" effort, arguing the bill was thoroughly vetted through both chambers and aligns state law with an upcoming federal ban Congress approved last year.

Meanwhile, 17 Senate Democrats filed legislation this week to fully legalize marijuana under federal law, moving in the opposite direction from the Trump administration's approach of merely reclassifying cannabis. The competing federal strategies reveal a deepening split: one path leads toward comprehensive legalization and a regulated national market; the other toward rescheduling within the existing prohibition framework. 🤔 THINK ABOUT IT Cannabis has never caused a recorded overdose death in human history, while alcohol kills approximately 95,000 Americans annually and prescription opioids kill over 16,000 per year—yet one remains federally prohibited while the other two remain legal and heavily marketed. The Senate bill represents the most direct challenge to Schedule I status in decades, though its prospects in a divided Congress remain uncertain.

State-level momentum continues unevenly. Virginia just legalized recreational cannabis sales, joining a growing number of states moving toward adult-use markets. However, Pennsylvania's adult-use legalization appears stalled again after years of failed attempts, and a medical cannabis initiative in Idaho fell short of qualifying for the general election ballot, leaving that state among the most restrictive in the nation. 🚀 THIS IS COOL The patchwork reflects genuine policy experimentation at the state level—some jurisdictions are building functional regulatory systems that generate tax revenue and prevent unregulated markets, while others maintain blanket prohibitions despite constituent demand.

The Missouri lawsuit highlights a specific tension: when federal law bans intoxicating hemp products but states maintain different rules, businesses face legal landmines. Craig Katz, government relations manager for MNG 2005, noted that lawmakers often lack understanding of cannabis industry mechanics, resulting in legislation that "doesn't make a whole heck of a lot of sense." The bill's definitions allegedly classify identical products as both "hemp" and "marijuana" depending on the provision, creating enforcement chaos. Without clarity, smoke shops operating legally today could face felony charges in November, and law enforcement won't know which products to seize.

The federal Democrats' legalization bill stands in sharp contrast to state-level bans like Missouri's, which align with federal prohibition rather than push against it. If Congress passes federal legalization, states like Missouri would face a choice: maintain bans despite federal legality, or align with the new national standard. The lawsuit may resolve before that reckoning arrives—but it signals that the hemp and cannabis industry is prepared to fight vague state restrictions in federal court, especially when those restrictions eliminate legal products currently generating revenue and serving consumers, including veterans using THC for PTSD and chronic pain management.

July 19, 2026

Intoxicating hemp products are facing legal and political crossfire across multiple states as federal policy uncertainty creates conflicting regulatory approaches. A coalition of hemp businesses filed a federal lawsuit Thursday in Missouri's U.S. District Court for the Western District, challenging a statewide ban set to take effect November 12 that would eliminate THC seltzers, hemp beverages, and other intoxicating hemp products currently sold in smoke shops, bars, and grocery stores. The lawsuit argues that Missouri's HB2641 contains "unconstitutionally vague" definitions for hemp and marijuana that would confuse businesses, law enforcement, and prosecutors alike. Craig Katz, government relations manager for MNG 2005, Inc.—parent company of 55 CBD Kratom stores nationwide—pointed directly at legislative overreach: "A lot of this stuff is kind of in the weeds. It's very difficult to understand. And when people are trying to legislate it, if they don't understand it, you come up with something like HB2641, which doesn't make a whole heck of a lot of sense." The coalition includes the Missouri Hemp Trade Association and Wisconsin-based Lifted Liquids Inc., all facing the elimination of a legal business sector.

The Missouri ban largely mirrors an upcoming federal prohibition that Congress approved last year, though the state bill includes conditional language: if Congress reverses course, Missouri would only permit intoxicating hemp products through licensed marijuana dispensaries, and if Congress delays the ban for a couple years, Missouri law would still ban all products except intoxicating beverages. 💰 MONEY MOVES Currently, unregulated intoxicating hemp products with as much as 1,000 mg of THC sell openly in Missouri's smoke shops, operating completely outside the state's licensed marijuana regulatory framework. The legislation tasks Missouri Attorney General Catherine Hanaway with enforcement, while Gov. Mike Kehoe and state health officials declined comment on pending litigation. Rep. Dave Hinman, the bill's sponsor, dismissed the lawsuit as a "Hail Mary" effort, arguing the legislation was thoroughly vetted through the House and Senate before the governor signed it.

The regulatory whiplash extends beyond Missouri. A federal district court judge in Toledo ruled recently that Ohio state officials are barred from enforcing the state's ban on hemp-derived intoxicating cannabinoids in beverages—but only for the 10 companies that filed a lawsuit and their vendors, creating a fragmented enforcement landscape. Similar hemp product bans have been debated in multiple states since 2023, with most failing to pass until this year's coordinated push. 🤔 THINK ABOUT IT Lawmakers are moving to ban a product category that has never killed anyone while alcohol—a federally legal substance that kills approximately 95,000 Americans annually—remains freely available in convenience stores. Meanwhile, at the federal level, Senate Democrats filed legislation to fully legalize marijuana under federal law as the Trump administration moves to merely reclassify it, signaling deepening divisions over cannabis policy direction even as state-level prohibition efforts accelerate.

The legal and political clash reflects genuine uncertainty about federal hemp policy and whether Congress will maintain its ban or reverse course. What remains clear is that Missouri's ban was designed to preemptively align state law with federal direction—and that the hemp industry, whose businesses operated legally under federal farm bill provisions until Congress decided otherwise, is fighting to survive in the gap between state and federal authority. The lawsuit arguments about vague definitions point to a real problem: legislators attempting to regulate a product category they may not fully understand, creating rules that could confuse enforcement or generate unintended consequences. The court will ultimately decide whether Missouri's ban survives constitutional scrutiny, but the broader pattern is visible—states are moving faster to eliminate intoxicating hemp products than courts or Congress appear to be moving toward resolution.

July 19, 2026

# THC & Politics Briefing

A federal court in Ohio just handed hemp businesses a significant win, but the legal war over intoxicating hemp products is spreading across state lines with dramatically different outcomes. On Monday, U.S. District Judge Jeffrey Helmick ruled that Ohio cannot enforce its ban on hemp-derived intoxicating cannabinoids in beverages against the 10 companies that sued—finding that Senate Bill 56 unconstitutionally discriminates against out-of-state businesses. Judge Helmick was blunt: the state redefined federally legal hemp products as illegal marijuana, then prohibited companies from selling them unless they had a physical presence in Ohio. "None of the defendants have rebutted plaintiffs' assertion that the legislature considered implementing age minimums and potency testing for all intoxicating hemp products," Helmick wrote, "and no defendant has explained why these non-discriminatory alternatives are inadequate." 💰 MONEY MOVES That preliminary injunction protects those 10 companies and their vendors from enforcement while the case proceeds—a crucial lifeline for businesses operating in what has become a patchwork regulatory nightmare.

Missouri, however, is pushing in the opposite direction with far more aggressive legislation. A coalition of hemp businesses filed a federal lawsuit this week challenging Missouri's statewide ban on intoxicating hemp products, set to take effect November 12. The bill—HB2641, which Governor Mike Kehoe signed early this year—will remove THC seltzers from bars and grocery stores and shut down the unregulated smoke shop market where products currently contain as much as 1,000 mg of THC. The industry coalition, which includes MNG 2005 (parent company of 55 CBD Kratom stores nationwide), the Missouri Hemp Trade Association, and Wisconsin-based Lifted Liquids Inc., argues the law contains "unconstitutionally vague" definitions that leave businesses, law enforcement, and prosecutors confused about what's actually banned. Craig Katz, compliance manager for MNG, pointed to lawmakers' fundamental lack of understanding: "When people are trying to legislate it, if they don't understand it, you come up with something like HB2641, which doesn't make a whole heck of a lot of sense."

The Missouri bill does align state law with an upcoming federal ban Congress approved last year—but it goes further. If Congress reverses course and allows these products, Missouri would only permit them in licensed marijuana dispensaries. If Congress delays the ban for a couple years, Missouri would still ban all products except intoxicating beverages. Bill sponsor Rep. Dave Hinman (R-O'Fallon) called the lawsuit "a Hail Mary" and predicted Missouri would simply "mirror the federal government." The named defendants—Governor Kehoe, Attorney General Catherine Hanaway, and Sarah Wilson of the Department of Health and Senior Services—have declined comment since litigation is pending. Hanaway's office said it hadn't yet been served. 🤔 THINK ABOUT IT Two federal courts are simultaneously hearing cases about the same federal hemp products, reaching opposite conclusions about state authority to ban them—suggesting the Supreme Court may eventually need to resolve whether states can eliminate legal hemp commerce to create a marijuana monopoly for licensed dispensaries.

Meanwhile, the federal landscape continues shifting. Seventeen Senate Democrats filed legislation this week to fully legalize marijuana under federal law, presenting a direct contrast to the Trump administration's approach of merely reclassifying cannabis from Schedule I to Schedule III. The federal bill represents the most aggressive legalization push in Congress, even as states remain deeply divided. Pennsylvania's legalization effort appears dead again after stalling in the legislature, while multiple states grapple with how to handle hemp products that are federally legal but increasingly unwelcome at the state level. The Ohio ruling suggests that outright bans face constitutional challenges under the Commerce Clause—a potential opening for hemp businesses in states considering similar prohibitions. 🚀 THIS IS COOL Judge Helmick's decision specifically highlighted that potency testing and age minimums could accomplish public health goals without discriminating against interstate commerce, giving other states a roadmap for regulation without elimination.

What emerges from Missouri's lawsuit and Ohio's court victory is a fundamental tension: states want to control intoxicating cannabinoid products, but the Constitution may not let them do it by favoring in-state licensed businesses over federally compliant out-of-state hemp producers. The unregulated hemp market—currently selling products with 1,000+ mg of THC in smoke shops—exists precisely because federal law permits it and state bans haven't stuck. As Congress debates full legalization while states implement conflicting bans, the courts are becoming the real legislature, deciding whether prohibition or regulation is the constitutional path forward.

July 18, 2026

# Federal Rescheduling Accelerates While States and Congress Chart Conflicting Paths

President Trump's December 2025 executive order on medical marijuana is now moving from policy to implementation. In April 2026, the Justice Department and DEA announced immediate rescheduling of FDA-approved marijuana products and state-regulated medical marijuana from Schedule I to Schedule III, with a broader administrative hearing set for June 29, 2026. 🚀 THIS IS COOL This action follows decades of federal gridlock: the FDA found credible scientific support for marijuana's use in treating chronic pain (affecting nearly 1 in 4 American adults), nausea and vomiting from chemotherapy, and anorexia related to medical conditions. The move recognizes that over 30,000 licensed healthcare practitioners across 43 jurisdictions are already recommending medical marijuana to more than 6 million registered patients—a reality that federal policy had ignored for over 50 years despite the National Institute on Drug Abuse and Department of Health and Human Services both supporting rescheduling.

💰 MONEY MOVES The rescheduling decision carries immediate economic and research implications. Moving marijuana from Schedule I—defined as having no medical use and high abuse potential—to Schedule III clears regulatory pathways for pharmaceutical research, manufacturer licensing, and clinical trials that federal law had blocked since the 1970 Controlled Substances Act. Acting Attorney General Todd Blanche framed the shift as delivering "on President Trump's promise to expand Americans' access to medical treatment options," while DEA Administrator Terry Cole emphasized that the action maintains "strict federal controls against illicit drug trafficking." The phased approach—immediate rescheduling of FDA-approved products and state-licensed medical marijuana, followed by a formal hearing for broader reclassification—gives researchers and patients clarity while the administrative process continues.

Meanwhile, Congress remains fractured on cannabis policy. In July 2026, Senate Democrats filed legislation to fully legalize marijuana under federal law, positioning their bill against Trump's reclassification-only approach. The distinction matters: rescheduling allows research and medical access but maintains federal prohibition, while legalization would remove cannabis from the Controlled Substances Act entirely. This split reflects a deeper tension. Forty states plus D.C. already have medical marijuana programs, yet federal law technically classifies those patients and their doctors as violating federal statute—a legal contradiction the Supreme Court has noted. In the 2026 Farm Bill debate, the House Agriculture Committee approved the legislation on a 34-17 vote but rejected amendments to delay a pending federal ban on hemp-derived THC products scheduled for November 2026, frustrating hemp industry stakeholders and advocates who argue for comprehensive regulation rather than outright prohibition.

State-level momentum tells a different story. 🚀 THIS IS COOL A recent study found that opioid use dropped in states that legalized recreational cannabis—a public health outcome worth noting given that prescription opioids kill over 16,000 Americans annually. Yet state-level progress remains uneven. Pennsylvania's adult-use legalization efforts appear stalled again, while Oklahoma's governor declared the state's medical marijuana program "failed" despite robust patient enrollment. These contradictions expose a market struggling with fragmented regulation: Missouri fined cannabis cultivators for using out-of-state seeds, and Ohio's Attorney General sued multistate operators for anti-competitive practices. The lack of federal consistency creates enforcement chaos that only legalization or uniform rescheduling can resolve.

🤔 THINK ABOUT IT Federal drug policy has now reached an inflection point. Schedule III status allows medical research on a substance that has never caused a recorded overdose death in human history, while Schedule I maintains that same substance has no medical use—a contradiction now being formally tested in federal court. The Trump administration's reclassification strategy sidesteps full legalization but opens the research floodgates and acknowledges state medical programs as legitimate. Senate Democrats want to go further. Congress can't agree on hemp-derived THC. And forty states have already made medical marijuana legal, forcing the federal government to either catch up or enforce prohibition against millions of patients and doctors. The June 2026 DEA hearing will likely determine which direction federal policy moves next—and whether state-level reality finally forces Washington to choose between reclassification, legalization, or maintaining a three-decade legal fiction that cannabis has no medical use.

July 18, 2026

# Federal Cannabis Reform Splits Along Philosophical Lines As States Move Ahead

Senate Democrats filed legislation this week to fully legalize marijuana under federal law, marking a sharp departure from the Trump administration's more modest approach of rescheduling the drug from Schedule I to Schedule III. The competing visions highlight a fundamental divide in how Washington views cannabis: Democrats are pushing for outright legalization and expungement of prior convictions, while the Trump administration is signaling it will pursue reclassification that acknowledges some medical value without removing the substance from controlled status entirely. The DEA finalized the rescheduling to Schedule III in June 2026, a historic shift after more than 50 years of Schedule I classification, but that move hasn't satisfied legalization advocates who argue it doesn't go far enough.

The rescheduling decision itself carries real implications for the cannabis industry and medical research. 🚀 THIS IS COOL Moving marijuana to Schedule III means researchers can now conduct federally-approved clinical trials with fewer bureaucratic barriers, potentially unlocking the scientific research that Schedule I restrictions had effectively frozen for decades. The reclassification also reduces criminal penalties and allows pharmaceutical companies to develop cannabis-derived medications without the stringent controls that previously applied. However, Schedule III status still means the substance remains federally illegal for recreational use, maintains criminal penalties, and doesn't address interstate commerce or banking access—issues that full legalization would resolve.

State-level action is already outpacing federal movement. Pennsylvania introduced legislation to award medical marijuana licenses specifically to small, diverse, and disadvantaged businesses, recognizing that cannabis legalization presents an opportunity to build equitable wealth in communities historically harmed by prohibition. Indiana regulators are similarly monitoring federal developments before finalizing their own regulatory framework, with lawmakers already drafting legalization bills. 💰 MONEY MOVES This state-by-state approach creates a patchwork economy where cannabis businesses in some states operate with federal banking access and tax deductions unavailable in others, fragmenting what could be a unified national market worth billions annually.

The gap between rescheduling and legalization matters more than the headlines suggest. Rescheduling addresses research and medical access but leaves the core prohibition intact—federal prosecutors can still pursue cannabis cases under federal law, banking institutions still refuse service to cannabis businesses due to federal restrictions, and patients in states with legal cannabis remain technically in violation of federal law. 🤔 THINK ABOUT IT The DEA reclassified a substance from Schedule I (defined as having no accepted medical use) to Schedule III (having accepted medical use but high abuse potential) based on the same plant that has never caused a recorded overdose death in human history, while alcohol—which kills approximately 95,000 Americans annually—remains completely legal and unscheduled. That contradiction isn't about science; it's about policy choices made decades ago and never fully reconsidered.

The Democrats' legalization push represents a bet that public opinion has shifted enough to force comprehensive federal change. Polling consistently shows majority support for legalization across demographic lines, and with medical rescheduling now a done fact, the political conversation has moved from "should we study this?" to "should we allow this entirely?" Full legalization would unlock interstate commerce, resolve banking conflicts, expunge prior convictions, and establish uniform tax and regulatory standards—outcomes that rescheduling alone cannot deliver. Whether the Senate bill gains traction will depend on whether momentum from rescheduling translates into appetite for the more ambitious step of removing cannabis from the Controlled Substances Act entirely.